<DOC>
	<DOCNO>NCT02140060</DOCNO>
	<brief_summary>The purpose study evaluate Travoprost/Brinzolamide fix combination ( Trav/Brinz ) administer twice daily compare marketed component ( TRAVATAN Z® solution AZOPT® suspension ) unfixed combination TRAVATAN Z® plus AZOPT® lower intraocular pressure ( IOP ) .</brief_summary>
	<brief_title>6-Week Proof-of-Concept Study Travoprost/Brinzolamide Ophthalmic Suspension Subjects With Open-Angle Glaucoma Ocular Hypertension</brief_title>
	<detailed_description>This study divide two phase conduct sequence . Phase I Screening/Eligibility Phase , include Screening Visit , follow two Eligibility Visits . Phase II randomize , double-masked , 6-week Treatment Phase include on-therapy visit Week 2 Week 6 . Travoprost administer 1 3 concentration level ( A-C ) , A=lowest C=highest .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Brinzolamide</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Diagnosed openangle glaucoma ( include openangle glaucoma pseudoexfoliation pigment dispersion ) ocular hypertension ; IOP within protocolspecified range Eligibility 1 2 Visits . Mean IOP must &gt; 36 mmHg time point ; Able understand sign inform consent form ; Other protocolspecified inclusion criterion may apply . Woman childbearing potential currently pregnant , intend become pregnant study period , breastfeeding , use adequate birth control method prevent pregnancy throughout study ; Unable discontinue IOPlowering ocular medication ( ) per appropriate washout schedule prior E1 Visit ; Chronic , recurrent severe inflammatory eye disease ; Ocular trauma within past 6 month prior Screening Visit ; Ocular infection ocular inflammation within past 3 month prior Screening Visit ; Clinically relevant progressive retinal disease retinal degeneration , diabetic retinopathy , retinal detachment ; Bestcorrected visual acuity ( BCVA ) score bad 55 ETDRS letter ( equivalent approximately 0.60 logMAR , 20/80 Snellen , 0.25 decimal ) ; Other ocular pathology ( include severe dry eye ) may , opinion Investigator , preclude administration topical prostaglandin analogue topical carbonic anhydrase inhibitor ; Intraocular surgery within past 6 month prior Screening Visit ; Ocular laser surgery within past 3 month prior Screening Visit ; Any abnormality prevent reliable applanation tonometry ; Any condition include severe illness would make subject , opinion Investigator , unsuitable study ; History hepatic renal disease would preclude safe administration carbonic anhydrase inhibitor ( CAI ) opinion Investigator ; Hypersensitivity prostaglandin analogue , topical oral CAIs , sulfonamide derivative , component study medication opinion Investigator ; Recent ( within 4 week Eligibility 1 Visit ) use high dose ( &gt; 1 g daily ) salicylate therapy ; Use additional topical systemic ocular hypotensive medication study ; Concurrent use glucocorticoid administer route ; Less 30 day stable dose regimen Screening Visit medication ( exclude IOPlowering treatment ) substance administer route use chronic basis may affect IOP ( ie , β adrenergic block agent ) ; Therapy another investigational agent within 30 day prior Screening Visit ; Other protocolspecified exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Glaucoma</keyword>
	<keyword>Ocular</keyword>
	<keyword>Hypertension</keyword>
	<keyword>OAG</keyword>
	<keyword>POAG</keyword>
	<keyword>OHT</keyword>
</DOC>